Physician profile
Taylor Shoffner
NPI 1710590823
$3,973.33
in general payments reported to CMS, 2019-2025
20 companies · $25.13 in 2025
The $25.13 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,390 · 2022: $474 · 2023: $717 · 2024: $367 · 2025: $25.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,340.19 | 2021 | |
| Abbvie INC. | $901.21 | 2021-2024 | |
| Novo Nordisk INC | $603.88 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $144.23 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $124.99 | 2023 | Inpefa |
| Indivior INC. | $112.81 | 2021-2024 | Sublocade |
| Actelion Pharmaceuticals US, INC. | $110.00 | 2024 | Uptravi, Opsumit |
| Dexcom, INC. | $108.34 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $98.90 | 2021-2024 | |
| Lilly USA, LLC | $74.60 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Genentech USA, INC. | $60.25 | 2021-2022 | |
| Orexo US, INC. | $51.71 | 2021-2023 | Zubsolv |
| Amgen INC. | $45.52 | 2021-2024 | Repatha, Otezla |
| Braeburn INC. | $39.12 | 2024 | Brixadi |
| Gilead Sciences, INC. | $36.08 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.89 | 2024 | Breztri, Airsupra |
| Sumitomo Pharma America, INC. | $28.48 | 2024 | Gemtesa |
| Boston Scientific Corporation | $25.13 | 2025 | Wavewriter Alpha Prime 16 |
| Amarin Pharma, INC. | $24.36 | 2021 | |
| Glaxosmithkline, LLC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Shoffner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.